Castle Biosciences, Inc. CSTL
Set alert
35.21 USD +0.27 +0.76%
As of Nov 3, 1:41 PM ET
34.73 Day range 36.00
17.72 52-week range 44.28
- YTD
- -9.50%
- 1 year
- +35.46%
- Open
- 35.32
- Prev close
- 34.94
- Mkt cap
- 1.08B
- Vol
- 197.96K
- Avg vol
- 372.19K
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 34.73
- High
- 36.00
- Forward P/E
- -37.37
- Beta
- 0.95
- Short ratio
- 5.17
- Inst. own
- 90.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 34.22
- 200-d avg
- 28.53
- 1y target
- 46.70
2Y chart
Events in this range
- Aug 4, 2025Earnings: 0.15; estimate -0.51; surprise 129.41%
- Nov 3, 2025Earnings: -0.02; estimate -0.34; surprise 94.12%
- Feb 26, 2026Earnings: -0.08; estimate -0.23; surprise 65.22%
- Feb 27, 2026Rating: Baird · Outperform → Outperform
- Apr 20, 2026Rating: Canaccord Genuity · Buy → Buy
- May 6, 2026Earnings: -0.49; estimate -0.49; surprise 0%
- May 7, 2026Rating: Baird · Outperform → Outperform
- May 13, 2026Rating: BTIG · Buy → Buy
- Jun 25, 2026Rating: Roth Capital · — → Buy
- Jul 30, 2026Earnings: -0.07; estimate -0.40697; surprise 82.8%
- Aug 3, 2026Rating: BTIG · Buy → Buy
Signals (76)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| RSI: Overbought | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| RSI: Overbought | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
Newest 20 of 76.
Key statistics
- Market cap
- 1.07B
- Enterprise value
- 905.06M
- Trailing P/E
- 0.00
- Forward P/E
- -37.37
- PEG ratio
- 0.00
- Price / sales
- 2.99
- Price / book
- 2.27
- EPS (TTM)
- -0.64
- Beta
- 0.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -5.43%
- Revenue (TTM)
- 357.28M
- Revenue growth
- 20.10%
- Free cash flow
- -7.26M
- Total cash
- 266.80M
- Total debt
- 36.65M
- Return on equity
- -4.20%
- Shares outstanding
- 30.55M
- Short % of float
- 6.76%
- 50-day average
- 34.22
- 200-day average
- 28.53
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 46.70 +32.7% upside
Now 35.21
- Target (low)
- 35.00
- Target (mean)
- 46.70
- Target (high)
- 60.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy0
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.346.
Financials — quick view
CSTL Revenue — quarterly 103.55M
CSTL Net income — quarterly -2.06M
CSTL EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.348 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.40697 | -0.07 | +0.34 | +82.80% |
| May 6, 2026 | Mar 31, 2026 | -0.49 | -0.49 | 0.00 | 0.00% |
| Feb 26, 2026 | Dec 31, 2025 | -0.23 | -0.08 | +0.15 | +65.22% |
| Nov 3, 2025 | Sep 30, 2025 | -0.34 | -0.02 | +0.32 | +94.12% |
| Aug 4, 2025 | Jun 30, 2025 | -0.51 | 0.15 | +0.66 | +129.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 2026 | BTIG | main | Buy | Buy |
| Jun 25, 2026 | Roth Capital | init | — | Buy |
| May 13, 2026 | BTIG | main | Buy | Buy |
| May 7, 2026 | Baird | main | Outperform | Outperform |
| Apr 20, 2026 | Canaccord Genuity | main | Buy | Buy |
| Feb 27, 2026 | Baird | main | Outperform | Outperform |
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- castlebiosciences.com
News
- Castle Biosciences to Participate in Upcoming Investor Conferences
- Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
- Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells Investors
- Castle Biosciences To Present New Data From Three Studies Evaluating Its TissueCypher Barrett's Esophagus Test At ACG 2026 Annual Scientific Meeting And Postgraduate Course
- ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
- Castle Biosciences (NASDAQ:CSTL) Stock Price Down 6.1% Following Insider Selling
- Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,034 Shares of Stock
- Castle Biosciences To Present New Data On DecisionDx-Melanoma At EADV Congress 2026
- Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
- New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
Your note
Sign in to keep a note on CSTL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADBURY DANIEL M | Director | Conversion of Exercise of derivative security | May 21, 2026 | 35,631 |
| CAPLE KIM | Director | Conversion of Exercise of derivative security | May 21, 2026 | 36,121 |
| COTTON RODNEY | Director | Conversion of Exercise of derivative security | May 21, 2026 | 32,998 |
| GOLDBERG ELLEN | Director | Conversion of Exercise of derivative security | May 21, 2026 | 40,921 |
| HARRISON MILES D | Director | Conversion of Exercise of derivative security | May 21, 2026 | 35,631 |
| JUVENAL TOBIN W | Officer | Sale | Oct 25, 2026 | 45,431 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.78% | 3,291,963 | 115.02M | Jun 29, 2026 |
| RTW Investments LP | 9.09% | 2,778,335 | 97.08M | Jun 29, 2026 |
| Principal Financial Group, Inc. | 5.65% | 1,726,648 | 60.33M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.01% | 1,226,497 | 42.85M | Jun 29, 2026 |
| Acadian Asset Management. LLC | 3.01% | 918,668 | 32.10M | Jun 29, 2026 |
| Allianz Asset Management GmbH | 2.88% | 879,258 | 30.72M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.79% | 852,704 | 29.79M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd. | 2.60% | 793,438 | 27.72M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.54% | 776,298 | 27.12M | Sep 29, 2026 |
| Principal Funds, Inc-SmallCap Fund | 2.37% | 725,138 | 25.34M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.12% | 342,655 | 11.97M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.07% | 327,806 | 11.45M | Jul 30, 2026 |